JAK3 and T-cell prolymphocytic leukemia: In contrast, constitutively activating JAK3 mutations—variously impacting the FERM, SH2, pseudokinase and kinase domains—have been detected in in several cases of human hematopoietic neoplasms, specifically cutaneous T cell lymphoma (CTCL) [11, 45], intestinal T cell lymphoma [49], T cell acute lymphoblastic leukemia (T-ALL) [3, 48], T cell prolymphocytic leukemia (T-PLL) [6], Natural killer T cell lymphoma (NKTCL) [27], as well as acute megakaryoblastic leukemia (AMKL) [25, 56, 64].